ROCKAWAY, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference. Mr. Goldberger will also be available for one-on-one meetings held throughout the conference on September 26 and 27, 2023.
iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference:
Date: Tuesday, September 26, 2023
Time: 12:00 PM EDT
Event: Company presentation
Virtual viewers: https://www.webcaster4.com/Webcast/Page/2992/49116
For more information regarding the conference and to register to watch the presentation live, please visit the conference page here.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Contact:
ECOR Investor Relations
(973) 302-9253
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$9.94 |
Daily Change: | -0.15 -1.49 |
Daily Volume: | 89,338 |
Market Cap: | US$64.110M |
November 13, 2024 September 10, 2024 August 07, 2024 August 01, 2024 June 25, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB